KRAS and neoplasm: Regarding the clinical features of early CRNUCs (LGD, HGD, or T1 carcinoma), there was no significant difference in the tumor location, inflammation of background mucosa, clinical course of UC, or type of UC between the patients with and without KRAS/BRAF mutations (Figure S2).